This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Aptose Biosciences Inc.
Drug Names(s): GTI-2501
Description: GTI-2501 is an antisense drug that specifically targets the R1 component of ribonucleotide reductase, which is required for DNA synthesis and cell division. GTI-2501 has also shown marked antitumor activity in a wide variety of preclinical cancer models, including prostate cancer.
Additional information available to subscribers only: